NICE Clears MS Treatment Option Suitable During Pregnancy
NICE backs natalizumab for highly active relapsing MS.
NICE backs natalizumab for highly active relapsing MS.
NICE proposes age-based CA125 testing to improve early diagnosis.
Sanofi has entered a strategic collaboration with Earendil Labs worth up to $2.56B to discover bispecific antibodies.
AbbVie has licensed ex-China rights to Zelgen’s DLL3 trispecific T-cell engager ZG006 in a deal worth up to $1.2B.